[go: up one dir, main page]

UY27523A1 - Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica - Google Patents

Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica

Info

Publication number
UY27523A1
UY27523A1 UY27523A UY27523A UY27523A1 UY 27523 A1 UY27523 A1 UY 27523A1 UY 27523 A UY27523 A UY 27523A UY 27523 A UY27523 A UY 27523A UY 27523 A1 UY27523 A1 UY 27523A1
Authority
UY
Uruguay
Prior art keywords
antiangiogen
heptapeptides
hexa
penta
tetra
Prior art date
Application number
UY27523A
Other languages
English (en)
Inventor
Fortuna Haviv
Michael Bradley
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/000,540 external-priority patent/US20030119745A1/en
Priority claimed from US10/000,711 external-priority patent/US20030105025A1/en
Priority claimed from US10/263,811 external-priority patent/US20030105022A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY27523A1 publication Critical patent/UY27523A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los compuestos de fórmula (SEQ ID NO:2) y (SEQ ID NO:3), que son útiles para el tratamiento de condiciones causadas por la angiogénesis o que son exacerbadas por la misma. También se describen composiciones farmacéuticas que comprenden tales compuestos, métodos de tratamiento en los que se los utiliza y métodos para inhibir la angiogénesis.
UY27523A 2001-10-31 2002-10-30 Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica UY27523A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/000,540 US20030119745A1 (en) 2001-10-31 2001-10-31 HEXA- and heptapeptides having antiangiogenic activity
US10/000,711 US20030105025A1 (en) 2001-10-31 2001-10-31 Tri-and tetrapeptides having antiangiogenic activity
US10/263,811 US20030105022A1 (en) 2001-10-31 2002-10-04 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity

Publications (1)

Publication Number Publication Date
UY27523A1 true UY27523A1 (es) 2003-05-30

Family

ID=32659830

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27523A UY27523A1 (es) 2001-10-31 2002-10-30 Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica

Country Status (6)

Country Link
EP (1) EP1451209A4 (es)
JP (1) JP2005512980A (es)
CA (1) CA2466152A1 (es)
MX (1) MXPA04004135A (es)
UY (1) UY27523A1 (es)
WO (1) WO2003037266A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125260A1 (en) * 2001-10-31 2003-07-03 Fortuna Haviv Tetra-and pentapeptides having antiangiogenic activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
CZ299639B6 (cs) * 1998-05-22 2008-10-01 Abbott Laboratories Peptidická antiangiogenní léciva

Also Published As

Publication number Publication date
EP1451209A2 (en) 2004-09-01
WO2003037266A3 (en) 2003-12-11
CA2466152A1 (en) 2003-05-08
WO2003037266A2 (en) 2003-05-08
EP1451209A4 (en) 2009-06-03
MXPA04004135A (es) 2004-07-08
JP2005512980A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
ATE263157T1 (de) Nematizide trifluorbutene
WO2003029264A3 (en) 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
PA8503301A1 (es) Compuestos para el tratamiento de la isquemia
ES2154167B1 (es) Aminoderivados ciclicos antagonistas del receptor ccr-3.
DE60112609D1 (en) Pyrazolopyridine
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
IS6658A (is) Ný efnasambönd
DOP2002000456A (es) Inhibidores de la alquin-aril fosfodiesterasa-4''
AU2003228770A8 (en) Substituted pyrazolopyrimidines
DE60324544D1 (de) Muskarin antagonisten
ES2243579T3 (es) Derivados de pirazolopirideno.
MXPA02012752A (es) Agentes herbicidas.
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
SE9901077D0 (sv) Novel use
ECSP034598A (es) Compuesto lactamico
DE60006825D1 (de) Serotonerge benzofurane
NO20002408L (no) 5-HT1F antagonister
UY27394A1 (es) Pedidos con actividad anti- angiogéna.
SE9904128D0 (sv) Novel compounds
GB0103045D0 (en) Organic Compounds
UY27523A1 (es) Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica
BR0000850B1 (pt) mistura de 3-metiloct-6-enóis 6-substituìdos, composição adorante contendo a referida mistura, bem como seu uso.
TW200503672A (en) 2-aminobenzoyl derivatives

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126